XML 26 R18.htm IDEA: XBRL DOCUMENT
v3.23.4

SHARE-BASED EMPLOYEE COMPENSATION | 9 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
SHARE-BASED EMPLOYEE COMPENSATION | (I) S hare-BASED EMPLOYEE COMPENSATION On August 3, 2023, our stockholders approved the Eagle Materials Inc. 2023 Equity Incentive Plan (the 2023 Plan), which reserves 1,425,000 shares for future grants of stock awards. Under the terms of the 2023 Plan, we can issue equity awards, including stock options, restricted stock units, restricted stock, and stock appreciation rights, to employees of the Company, members of the Board of Directors, consultants, independent contractors, and agents of the Company. The Compensation Committee of our Board of Directors specifies grant terms for awards under the Plan. Long-Term Compensation Plans OPTIONS In May 2023, under the 2013 Amended and Restated Incentive Plan (the Prior Plan), the Compensation Committee of the Board of Directors approved the granting to certain officers and key employees an aggregate of 2,296 performance-vesting stock options that will be earned only if certain performance conditions are satisfied (the Fiscal 2024 Employee Performance Stock Option Award). The performance criteria for the Fiscal 2024 Employee Performance Stock Option Award are based upon the achievement of certain levels of return on equity (as defined in the option agreements), ranging from 10.0% to 20.0%, for the performance periods described in the table below. All stock options in each performance period will be earned if the return on equity is 20.0% or greater. If the return on equity is less than 20% but at least 10% in any performance period, the amount of stock options earned in such period will be reduced proportionately using straight-line interpolation, such that approximately 66.7% of the amount of stock options granted will be earned if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0% during any performance period, all stock option awards for that performance period will be forfeited. The stock option performance periods are as follows:
|  | Options |  |  | Performance Period |  | Vesting Date
One-Year Performance Shares |  |  | 574 |  |  | April 1, 2023 to March 31, 2024 |  | May 2024
Two-Year Performance Shares |  |  | 574 |  |  | April 1, 2023 to March 31, 2025 |  | May 2025
Three-Year Performance Shares |  |  | 1,148 |  |  | April 1, 2023 to March 31, 2026 |  | May 2026
The stock options have a term of 10 years from the grant date. The Compensation Committee also approved the granting of 1,914 time-vesting stock options to the same officers and key employees, which vest ratably over three years (the Fiscal 2024 Employee Time-Vesting Stock Option Award). In August 2023, under the 2023 Plan, the Compensation Committee granted 1,348 options to members of the Board of Directors (the Fiscal 2024 Board of Directors Stock Option Award). Options granted under the Fiscal 2024 Board of Directors Stock Option Award vest one year after the grant date, and can be exercised from the date of vesting until their expiration on the tenth anniversary of the grant date. The Fiscal 2024 Employee Performance Stock Option Award, the Fiscal 2024 Employee Time-Vesting Stock Option Award, and the Fiscal 2024 Board of Directors Stock Option Award were valued at their grant date using the Black-Scholes option pricing model. The weighted-average assumptions used in the Black-Scholes model to value the option awards for fiscal 2024 are as follows:
Dividend Yield |  |  | 0.8 | %
Expected Volatility |  |  | 38.8 | %
Risk-Free Interest Rate |  |  | 3.7 | %
Expected Life |  | 6.0 years |
In addition to the stock options described above, we issue stock options to certain employees from time to time. Any options issued are valued using the Black-Scholes options pricing model on the grant date and expensed over the vesting period. Stock option expense for all outstanding stock option awards totaled approximately $0.5 million and $1.5 million for the three and nine months ended December 31, 2023, respectively, and $0.8 million and $2.7 million for the three and nine months ended December 31, 2022, respectively. At December 31, 2023, there was approximately $2.2 million of unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted-average period of 1.9 years. The following table represents stock option activity for the nine months ended December 31, 2023:
|  | Number of Shares |  |  | Weighted- Average Exercise Price |
Outstanding Options at March 31, 2023 |  |  | 436,949 |  |  | $ | 89.69 |
Granted |  |  | 5,558 |  |  | $ | 172.62 |
Exercised |  |  | (131,099 | ) |  | $ | 88.17 |
Cancelled |  |  | (1,000 | ) |  | $ | 73.37 |
Outstanding Options at December 31, 2023 |  |  | 310,408 |  |  | $ | 91.86 |
Options Exercisable at December 31, 2023 |  |  | 215,822 |  |  |  |
Weighted-Average Fair Value of Options Granted During the Year |  | $ | 69.84 |  |  |  |
The following table summarizes information about stock options outstanding at December 31, 2023:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  | Number of Shares Outstanding |  |  | Weighted- Average Remaining Contractual Life (in years) |  |  | Weighted- Average Exercise Price |  |  | Number of Shares Outstanding |  |  | Weighted- Average Exercise Price |
$59.32 - $81.28 |  |  | 113,490 |  |  |  | 5.91 |  |  | $ | 62.49 |  |  |  | 71,086 |  |  | $ | 63.67 |
$87.37 - $106.24 |  |  | 125,721 |  |  |  | 4.60 |  |  | $ | 95.77 |  |  |  | 122,005 |  |  | $ | 95.72 |
$118.27 - $166.75 |  |  | 71,197 |  |  |  | 8.34 |  |  | $ | 131.77 |  |  |  | 22,731 |  |  | $ | 130.79 |
|  |  | 310,408 |  |  |  | 5.94 |  |  | $ | 91.86 |  |  |  | 215,822 |  |  | $ | 88.86 |
At December 31, 2023, the aggregate intrinsic value of the outstanding and exercisable options was approximately $34.4 million and $24.6 million, respectively. The total intrinsic value of options exercised during the nine months ended December 31, 2023, was approximately $10.6 million. RESTRICTED STOCK In May 2023, under the Prior Plan, the Compensation Committee approved the granting to certain officers and key employees an aggregate of 45,693 shares of performance-vesting restricted stock that will be earned if certain performance conditions are satisfied (the Fiscal 2024 Employee Restricted Stock Performance Award). The performance criteria for the Fiscal 2024 Employee Restricted Stock Performance Award are based upon the achievement of certain levels of return on equity (as defined in the award agreement), ranging from 10.0% to 20.0%, for the performance periods described in the table below. All restricted shares in each performance period will be earned if the return on equity is 20.0% or greater. If the return on equity is less than 20% but at least 10% in any performance period, the amount of shares earned in such period will be reduced proportionately using straight-line interpolation, such that approximately 66.7% of the amount of shares issued will be earned if the return on equity is 10.0%. If the Company does not achieve a return on equity of at least 10.0% during any performance period, all awards for that performance period will be forfeited. The restricted share performance periods are as follows:
|  | Shares |  |  | Performance Period |  | Vesting Date
One-Year Performance Shares |  |  | 11,424 |  |  | April 1, 2023 to March 31, 2024 |  | May 2024
Two-Year Performance Shares |  |  | 11,424 |  |  | April 1, 2023 to March 31, 2025 |  | May 2025
Three-Year Performance Shares |  |  | 22,845 |  |  | April 1, 2023 to March 31, 2026 |  | May 2026
The Compensation Committee also approved the granting of 38,072 shares of time-vesting restricted stock to the same officers and key employees, which vest ratably over three years (the Fiscal 2024 Employee Restricted Stock Time-Vesting Award). The Fiscal 2024 Employee Restricted Stock Performance Award and the Fiscal 2024 Employee Restricted Stock Time-Vesting Award were valued at the closing price of the stock on the grant date and are being expensed over a three-year period. In August 2023, under the 2023 Plan, we granted 10,755 shares of restricted stock to members of the Board of Directors (the Fiscal 2024 Board of Directors Restricted Stock Award). Restrictions on these shares will lapse one year after the grant date. The Fiscal 2024 Board of Directors Restricted Stock Award was valued at the closing price of the stock on the grant date, and is being expensed over a one-year period. In addition to the restricted stock described above, from time to time we issue restricted stock to certain employees. These awards are valued at the closing price of the stock on the grant date and expensed over the vesting period. The fair value of restricted stock is based on the stock price on the grant date. The following table summarizes the activity for nonvested restricted shares during the nine months ended December 31, 2023:
|  | Number of Shares |  |  | Weighted-Average Grant Date Fair Value |
Nonvested Restricted Stock at March 31, 2023 |  |  | 219,084 |  |  | $ | 96.54 |
Granted |  |  | 97,257 |  |  | $ | 169.62 |
Vested |  |  | (35,958 | ) |  | $ | 146.24 |
Forfeited |  |  | (3,000 | ) |  | $ | 139.03 |
Nonvested Restricted Stock at December 31, 2023 |  |  | 277,383 |  |  | $ | 125.10 |
Expense related to restricted shares was approximately $4.0 million and $13.8 million for the three and nine months ended December 31, 2023, respectively, and $3.3 million and $11.0 million for the three and nine months ended December 31, 2022, respectively. At December 31, 2023, there was approximately $21.5 million of unearned compensation from restricted stock, which will be recognized over a weighted-average period of 1.7 years. The number of shares available for future grants of stock options, restricted stock units, stock appreciation rights, and restricted stock under the 2023 Plan was 1,411,804 at December 31, 2023.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration